UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2023

BioSig Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**001-38659**	**26-4333375**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

55 Greens Farms Road, 1st Floor **Westport, Connecticut**	**06880**
(Address of principal executive offices)	(Zip Code)

(203) 409-5444
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, par value $0.001 per share	BSGM	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On May 19, 2023, BioSig Technologies, Inc. (the "***Company***"), issued a press release, attached hereto as Exhibit 99.1, announcing that it is advancing the research and development of an artificial intelligence medical device platform in collaboration with technical advisory partner Reified Labs. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated June 27, 2023 (furnished herewith pursuant to Item 7.01)
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSIG TECHNOLOGIES, INC.

Date: June 27, 2023

By: /s/ Kenneth L. Londoner
Name: Kenneth L. Londoner
Title: Executive Chairman

BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Westport, CT, June 27, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is advancing the research and development of an artificial intelligence (AI) medical device platform in collaboration with technical advisory partner Reified Labs.

The platform's foundational machine learning model is anticipated to be based on integrated healthcare datasets, beginning with ECG and IECG data acquired by BioSig's first product, the PURE EP™ Platform. Electrophysiology-focused technological solutions developed under the terms of the collaboration may be integrated into PURE EP™ technology for potential commercial application.

Cambridge, Massachusetts-based Reified Labs, a provider of advanced artificial intelligence-focused technical advisory services to the life sciences industry, is led by Harvard- and MIT-trained Dr. Alexander D. Wissner-Gross, an award-winning computer scientist, physicist, entrepreneur, and author. BioSig's prior collaboration with Reified, established in 2019, has yielded multiple patent applications[1] and a research publication[2] on initial discoveries in AI-enhanced electrocardiogram lead placement mapping.

On June 20, 2023, Dr. Wissner-Gross delivered a keynote address at a prominent gathering of clinical leaders in Rochester, Minnesota, exploring the exciting possibilities that artificial intelligence brings to healthcare. In his speech, entitled "Unsupervised Medicine: The Next Wave of AI in Healthcare," Dr. Wissner-Gross reviewed recent research advances in unsupervised (or self-supervised) machine learning models. Such models appear to have dramatically accelerated overall progress toward artificial general intelligence (AGI), with one community forecast of the expected arrival date of AGI collapsing from 2043 to 2026 in the past two years alone. In describing AGI and how its applications can be accelerated in healthcare, Dr. Wissner-Gross used Reified's prior collaboration with BioSig as a case study.

"The cutting-edge work this collaboration started in early 2019 to lay a foundation in AI was ahead of the curve, and our initial findings may have several potentially valuable clinical applications worthy of further exploration," commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

"The application of AGI and digital signal processing to analyzing signals from the so-called human 'electrome' – the set of all electrical and ionic currents in the human body – continues to present a promising opportunity for realizing key medical advances relating to disorders of the peripheral nervous system," said Dr. Wissner-Gross. "We look forward to our forthcoming collaboration with BioSig."

About BioSig Technologies
BioSig Technologies is an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare's biggest priorities—saving time, saving costs, and saving lives.

The Company's first product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.

The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate[3]

---

[1] U.S. Patent Application Nos. 17/240,809 ("Methods, systems and media for reconstructing bioelectronic lead placement") and 17/411,955 ("Methods, systems and media for detrending bioelectronic signals").
[2] "*Computational Reconstruction of Electrocardiogram Lead Placement"*
[3] Global Market Insights Inc. March 08, 2022

Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For investor relations**:**
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133

For media inquiries:
Katie Freshwater
BioSig Technologies, Inc.
Vice President, Marketing
55 Greens Farms
Westport, CT 06880
kfreshwater@biosigtech.com
203-409-5444, x162